This article is more than 5 years old. Information may no longer be current.

Polycaprolactone dermal filler outlasts nonanimal stabilized hyaluronic acid filler

In a randomized, split-face study, researchers determined polycaprolactone-based dermal fillers offered longer-lasting results than nonanimal stabilized hyaluronic acid-based fillers for the treatment of nasolabial folds.

Forty patients between the ages of 31 and 60 years were enrolled in the single-center, prospective, randomized, split-face, controlled trial. Each patient received a novel biostimulatory polycaprolactone (PCL)-based dermal filler on one side of the face and nonanimal stabilized hyaluronic acid (NASHA)-based filler on the other. Follow-up occurred at 1, 3, 6, 9 and 12 months, and the researchers used the Wrinkle Severity Rating Scale (WSRS) and the Global Aesthetic Improvement Scale (GAIS) to evaluate treatment efficacy.

Hassan Galadari

A statistically significantly higher rate of improvement was found on the PCL filler side of patients' faces compared with the NASHA filler side in terms of scores on both the WSRS and GAIS at 6, 9 and 12 months after treatment, according to the researchers.

At months 9 and 12, total much improvement (TMI) - or the total GAIS rating of "very much improved" plus "much improved" - of 41% and 20%, respectively, was observed on the PCL side. On the NASHA side 0% TMI was observed, according to the researchers.

The researchers also noted that the injection volume with the PCL filler was less than the NASHA filler to achieve optimal effect.

Overall, both fillers were found to be well-tolerated and equally safe. - by Abigail Sutton

Disclosure: The researchers report no relevant financial disclosures.